Canada Continuous Glucose Monitoring Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 348.33 Million |
| Market Size (2027) | USD 390.24 Million |
| Market Size (2032) | USD 688.66 Million |
| Growth Rate (2027 - 2032) | 12.03 % |
| Market Concentration | Low |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Canada Continuous Glucose Monitoring Market Analysis by Mordor Intelligence
The Canada Continuous Glucose Monitoring Market size is expected to grow from USD 348.33 million in 2026 to USD 390.24 million in 2027 and is forecast to reach USD 688.66 million by 2032 at 12.03% CAGR over 2027-2032.
According to Diabetes Canada, at the beginning of the COVID-19 pandemic, studies showed that diabetes was one of the major comorbidities associated with the development of severe COVID-19-related adverse outcomes and mortality. Adults living with diabetes who contracted COVID-19 were at higher risk of developing adult respiratory distress syndrome, pneumonia, excessive uncontrolled inflammation responses, and a hypercoagulable state.
Early reports placed the odds of in-hospital death from COVID-19 to be 2.85 times higher in adults living with diabetes compared to patients without diabetes. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe, and improved inpatient glycemic outcomes played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.
CGM systems provide continuous visibility into glucose trends rather than isolated readings, enabling patients and healthcare professionals to identify patterns and respond to abnormal glucose levels. This capability strengthens the role of CGM in personalized diabetes management.
Furthermore, current continuous glucose monitoring systems enable users to review historical blood glucose trends through downloaded data or monitor real-time glucose levels on receiver displays. The newest CGM (continuous glucose monitoring) models, the Abbott Freestyle Libre 3, and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Market Trends and Insights
Rising Diabetes Prevalence in Canada is anticipated to boost the market studied.
In the current year, according to Diabetes Canada, more than 5.7 million Canadians are living with diagnosed diabetes (type 1 or type 2 diabetes); however, 11.7 million Canadians are living with diabetes or prediabetes, a condition that, if left unmanaged, can develop into type 2 diabetes. Diabetes is also costing the healthcare system USD 30 billion per year to treat people with diabetes.
Monitoring blood glucose levels serves as a useful adjunct to other measures of glycemia, including A1C. It is the optimal way to confirm and appropriately treat hypoglycemia. It can provide feedback on the results of healthy behavior interventions and antihyperglycemic pharmacological treatments. It can increase one's empowerment and adherence to treatment. It can also provide information to both the person with diabetes and their diabetes healthcare team to facilitate longer-term treatment modifications and titrations as well as shorter-term treatment decisions, such as insulin dosing for people with type 1 or type 2 diabetes. In situations where A1C does not accurately reflect glycemia, monitoring blood glucose is necessary to adequately monitor glycemia.
International and national diabetes-care initiatives increasingly emphasize improved access to monitoring technologies and stronger integration of diabetes management into primary healthcare. Such policy priorities can support broader adoption of CGM and other monitoring solutions.
The Canadian Diabetes Strategy (CDS) is a national partnership that includes the provinces and territories, many national health organizations and groups, and aboriginal communities across the country. The purpose of the CDS is to establish effective diabetes prevention and control strategies for Canada through its various partners to ensure that resources are deployed accordingly.
Rising disease prevalence and government-led awareness initiatives are expected to drive the growth of the studied market during the analysis period.
The Sensors Segment is Projected to Account for the Largest Share During the Forecast Period
Continuous glucose monitoring devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula that is inserted into the top layer of skin and uses samples of interstitial fluid to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels.
Innovation in sensor technology is focused on improving accuracy, wear duration, comfort, affordability, and ease of use. Emerging optical and other non-traditional sensing approaches could further expand the range of CGM solutions available to patients and improve long-term adoption.
Competitive Landscape
Market Concentration
A limited number of major players characterize the consolidated Canada continuous glucose monitoring market. Companies such as Abbott, Dexcom, and Medtronic foster innovation through organic growth strategies backed by substantial research and development (R&D) investments. They prioritize improvements in device accuracy, ease of use, connectivity, and data management capabilities. These ongoing product development initiatives reinforce their competitive positions and promote the adoption of continuous glucose monitoring systems across Canada.
Canada Continuous Glucose Monitoring Industry Leaders
-
Ascensia
-
Abbott
-
Dexcom
-
GlySens
-
Medtronic
- *Disclaimer: Major Players sorted in no particular order
Canada Continuous Glucose Monitoring Market Companies Covered in this Report
- Abbott Laboratories
- Dexcom
- Medtronic
- Ascensia
- GlySens
Read Analysis of Canada Continuous Glucose Monitoring Companies
Recent Industry Developments in Canada Continuous Glucose Monitoring Market
- October 2023: Dexcom launched its next-generation G7 continuous glucose monitor (CGM) in Canada for people with all types of diabetes aged two and older, including those who are pregnant, in the country.
- March 2023: Dexcom announced that all people with type 1 and type 2 diabetes in Manitoba, Canada, meet eligibility criteria for its G6 CGM. As of the company’s announcement, Manitoba is the only province in Canada that does not require an application for coverage preapproval.
Canada Continuous Glucose Monitoring Market Report Scope
Continuous glucose monitoring (CGM) is a method of tracking glucose levels throughout the day and night using a small sensor worn under the skin. It sends regular readings to a receiver or smartphone, helping people spot trends and manage diabetes. The Canadian continuous glucose monitoring market is segmented into components (sensors and durables). The report offers the value (in USD) and volume (in units) for the above segments.
Segmentation Overview
| Sensors |
| Durables |
| Component | Sensors |
| Durables |
Key Questions Answered in the Report
How big is the Canada Continuous Glucose Monitoring Market?
The Canada Continuous Glucose Monitoring Market size is expected to reach USD 390.24 million in 2027 and grow at a CAGR of 12.03% to reach USD 688.66 million by 2032.
What is the current Canada Continuous Glucose Monitoring Market size?
In 2026, the Canada Continuous Glucose Monitoring Market size is expected to reach USD 348.33 million.
Who are the key players in Canada Continuous Glucose Monitoring Market?
Ascensia, Abbott, Dexcom, GlySens and Medtronic are the major companies operating in the Canada Continuous Glucose Monitoring Market.
What years does this Canada Continuous Glucose Monitoring Market cover, and what was the market size in 2026?
In 2026, the Canada Continuous Glucose Monitoring Market size was estimated at USD 348.33 million. The report covers the Canada Continuous Glucose Monitoring Market historical market size for years: 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Canada Continuous Glucose Monitoring Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.